Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15642893 | 0.84 | HPGD (0.69) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL2910036 | 0.84 | SIRT6 (0.69) | MAPTSIRT6HTR6ALDH1A1L3MBTL1 | |
| SCHEMBL22174793 | 0.83 | MAPT (0.51) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL2553550 | 0.83 | MAPT (0.72) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL13981521 | 0.83 | SIRT6 (0.72) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL2926293 | 0.82 | HPGD (0.54) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL2204030 | 0.81 | MAPT (0.49) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL309624 | 0.81 | SIRT6 (0.74) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL40059 | 0.81 | HPGD (0.68) | MAPTCYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL22652221 | 0.81 | L3MBTL1 (0.51) | MAPTCYP1A2CYP2C19SIRT6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2021-05-06 | — | — | US | disclosed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 940/4885CYP1A2 4030/4885CYP2C19 4263/4885 |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | MAPT 940/4885CYP1A2 4030/4885CYP2C19 4263/4885 |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 817/4885CYP1A2 3721/4885CYP2C19 3966/4885 |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | MAPT 817/4885CYP1A2 3721/4885CYP2C19 3966/4885 |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 817/4885CYP1A2 3721/4885CYP2C19 3966/4885 |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MAPT 940/4885CYP1A2 4030/4885CYP2C19 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.